

Structure-activity relationships of ganoderma acids from *Ganoderma lucidum* as aldose reductase inhibitors

Fatmawati, Sri

Department of Chemistry, Faculty of Mathematics and Natural Sciences, Sepuluh Nopember Institute of Technology

Shimizu, Kuniyoshi

Department of Agro-environmental Sciences, Faculty of Agriculture, Kyushu University

Kondo, Ryuichiro

Department of Agro-environmental Sciences, Faculty of Agriculture, Kyushu University

<https://hdl.handle.net/2324/25651>

出版情報 : Bioorganic & Medicinal Chemistry Letters. 21 (24), pp.7295-7297, 2011-12-15.
Elsevier

バージョン :

権利関係 : (C) 2011 Published by Elsevier Ltd.



Structure-activity relationships of ganoderma acids from *Ganoderma lucidum* as aldose reductase inhibitors

Sri Fatmawati^{a,b}, Kuniyoshi Shimizu^{b*}, Ryuichiro Kondo^b

^aDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Sepuluh Nopember Institute of Technology, Kampus ITS-Sukolilo, Surabaya, Indonesia, 60111.

^bDepartment of Agro-environmental Sciences, Faculty of Agriculture, Kyushu University, Fukuoka, Japan, 812-8581.

*** Address for correspondence**

Kuniyoshi Shimizu

Department of Agro-environmental Sciences

Faculty of Agriculture

Kyushu University

Fukuoka, Japan, 812-8581.

Tel/Fax; +81-92-642-2811

E-mail: shimizu@agr.kyushu-u.ac.jp

Abstract

A series of lanostane-type triterpenoids, known as ganoderma acids were isolated from the fruiting body of *Ganoderma lucidum*. Some of these compounds were identified as active inhibitors of the *in vitro* human recombinant aldose reductase. To clarify the structural requirement for inhibition, some structure-activity relationships were determined. Our structure-activity studies of ganoderma acids revealed that the OH substituent at C-11 is an important feature and the carboxylic group in the side chain is essential for the recognition of aldose reductase inhibitory activity. Moreover, double bond moiety at C-20 and C-22 in the side chain contributes to improving aldose reductase inhibitory activity. In the case of ganoderic acid C2, all of OH substituent at C-3, C-7 and C-15 is important for potent aldose reductase inhibition. These results provide an approach to understanding the structural requirements of ganoderma acids from *G. lucidum* for aldose reductase inhibitor. This understanding is necessary to design a new-type of aldose reductase inhibitor.

Keywords : *Ganoderma lucidum*, structure-activity relationships, Ganodermataceae, aldose reductase inhibitor, ganoderma acid, triterpenoid

Diabetes mellitus is a metabolic disease characterized by high blood sugar levels ensuing from a deficiency in insulin secretion, insulin action, or both. As one of the most prevalent metabolic syndromes world-wide, this disease is characterized by hyperglycemia resulting in short-term metabolic changes in lipid and protein metabolism and long-term irreversible vascular and connective-tissue changes. These changes consist of diabetes-specific complications such as retinopathy, nephropathy and neuropathy, etc¹.

Aldose reductase (alditol:NAD(P)⁺ 1-oxidoreductase, EC 1.1.1.21) is the first enzyme in the polyol pathway. It is a cytosolic, monomeric oxidoreductase that catalyses the NADPH-dependent reduction of a wide variety of carbonyl compounds, including glucose. In a hyperglycemic condition, increased intracellular glucose results in increased enzymatic conversion to sorbitol, with concomitant decreases in NADPH. At the same time, another sorbitol dehydrogenase oxidizes sorbitol to fructose. However, in diabetic conditions, the glucose level in this pathway is increased, causing faster sorbitol production². The accumulation of sorbitol leads to diabetic complications. These inhibitors seem to offer the possibility of preventing the development of these long-term diabetic complications, despite high blood glucose levels and with no risk of hypoglycemia, since they have no effect on plasma glucose³. Hence, aldose reductase inhibitors (ARIs) have been known to offer a window for the treatment of diabetic complications.

A large variety of structurally diverse compounds have been identified to date as potent *in vitro* aldose reductase inhibitors. The currently known ARIs can be divided into four main classes according to their structures: (1) acetic acid derivatives, such as tolrestat and epalrestat; (2) cyclic imides such as sorbinil; (3) phenolic derivatives such as quercetin, and (4) phenylsulfonylnitromethane derivatives such as ZD 5522⁴. Although many aldose reductase inhibitors have been reported, lanostane-type triterpenoid is rarely reported as aldose reductase inhibitors⁵.

The fruiting body of *Ganoderma lucidum* (Leyss; Fr) Karst. (Ganodermataceae) is a well-known woody mushroom that is called “Lingzhi” in Chinese, “Reishi” in Japanese and “Yeongji” in Korean. It has been used as traditional medicine to increase youth, vigor and vitality. *G. lucidum* has been reported to produce many biologically active compounds such as polysaccharides and triterpenoids⁶. Over 120 triterpenoids have been isolated from *G. lucidum* and the genus *Ganoderma*⁷. Furthermore, this mushroom has long been reputed. The specific reported attributes of *G. lucidum* include cytotoxic⁸, anti-HIV⁹, 5 α -reductase inhibitor¹⁰, anti-inflammatory¹¹, anti-tumor¹², anti-microbial¹³, anti-cancer¹⁴, anti-fungal¹⁵ and anti-herpetic¹⁶ properties.

In a prior study, we screened 17 edible and medicinal mushrooms for aldose reductase inhibitory activities. We revealed that the MeOH extract of *G. lucidum* showed the strongest aldose reductase inhibitory activity. Additionally, the treatment of the EtOH extract of *G. lucidum* significantly decreased the galactitol accumulation in the eye lens of galactosemic rats¹⁷. As part of our ongoing search for aldose reductase inhibitors from natural sources, we evaluated both the activities of the fractions and constituents from the fruiting body of *G. lucidum*⁵. We selected CHCl₃

extract for further experiment because it has higher inhibition than that of EtOH or MeOH extract⁵. The biologically active constituents of this mushroom have mainly been examined for lanostane-type triterpenoids. From this mushroom, a new compound was isolated and confirmed to have strong aldose reductase inhibition¹⁸. Among the constituents isolated in this study, aldose reductase inhibitory activities have already been demonstrated in some compounds, but other analogs and the structure-activity relationships have not yet been fully confirmed. In the present study we investigated the structure-activity relationships of the aldose reductase inhibition against ganoderma acids isolated from *G. lucidum*.

The triterpenoids isolated from *G. lucidum* were divided into two groups. The first group is called ganoderma acids, with a carboxyl group at the side chain. The second group is namely ganoderma alcohols, with a hydroxyl group at the side chain. Acidic fraction mostly provides ganoderma acids and neutral fraction provides ganoderma alcohols¹⁹. Acidic fraction showed higher aldose reductase inhibition than that of neutral fraction, therefore we focused on acidic fraction⁵.

Phytochemical study of acidic fraction of the CHCl₃ extract from the fruiting body of *G. lucidum* led to the isolation of 13 ganoderma acids (**1-5**, **8-15**) and two their methyl esters (**6**, **7**) (Table 1). The compounds isolated from the acid fraction of the CHCl₃ extract of *G. lucidum* were ganoderic acid Df (**1**)¹⁸, ganoderic acid C6 (**2**)²⁰, ganoderenic acid A (**3**)²¹, ganoderic acid A (**4**)²², ganoderic acid J (**5**)²³, methyl ganoderate A (**6**)²², methyl ganoderenate A (**7**)²¹, ganoderic acid C2 (**8**)²⁴, and ganoderic acid G (**9**)²⁰, ganolucidic acid B (**10**)²⁵, ganoderic acid B (**11**)²², ganoderic acid K (**12**)²⁶, ganoderic acid H (**13**)²⁰, ganoderenic acid D (**14**)²¹ and ganoderic acid C1 (**15**)²⁴. The isolated compound **2** was identified as compound C6²⁰, which was recently named ganoderic acid C6²⁷⁻²⁹. We also synthesized methyl esters of **1** (**16**) and **8** (**17**).

The effects of the isolated compounds on aldose reductase were examined. The aldose reductase inhibitory activity was measured by a method previously reported by Fatmawati et al³⁰. Table 1 indicated that the IC₅₀ of ganoderic acid Df (**1**) is 22.8 μM, whereas its methyl ester (**16**) is more than 189.4 μM. Also, the IC₅₀ values of ganoderic acid C2 (**8**) and ganoderenic acid A (**3**) were estimated to be 43.8 μM and 119.2 μM, respectively. In contrast, methyl ganoderate C2 (**17**: IC₅₀ > 183.9 μM) and methyl ganoderenate A (**7**: IC₅₀ > 183.9 μM) were found to be much weaker than ganoderic acid C2 (**8**) and ganoderenic acid A (**3**). Thus, the carboxyl group of ganoderma acids is essential for revealing potent aldose reductase inhibitory activity. A previous paper reported that an aldose reductase inhibitor with a carboxyl group showed a charge that was complementary between its carboxyl group and aldose reductase³¹. The COOH hydrophilic head is similar to the heads of many aldose reductase inhibitors such as tolrestat and zopolrestat, and has the potential of binding to aldose reductase in the form (COO)⁻³².

Ganoderic acid Df (**1**) showed the highest inhibition against aldose reductase among the isolated compounds from *G. lucidum*. By comparing **1** and ganoderic acid C1 (**15**: IC₅₀ > 194.4 μM), the hydroxyl group at C-11 is responsible for the potent aldose reductase inhibition. **1** has a hydroxyl group at C-11, which is the only structural difference between it and the other isolated compounds.

Thus, the hydroxyl group at the C11-position is an important factor in obtaining enhanced potency of aldose reductase inhibitors in ganoderma acids.

Ganoderic acid C2 (**8**) and ganoderenic acid A (**3**) also showed high inhibitory activities. The aldose reductase inhibition of **8** was higher than that of **3**. **8** has a hydroxyl group at C-3, which is the only structural difference between it and ganoderic acid A (**4**: $IC_{50} > 193.5 \mu M$), which has a carbonyl group instead of a hydroxyl group at C-3. This is evidence that the hydroxyl group at C-3 in **8** is important with regard to the inhibitory activity based on the lower activity level of **3**. Also, in comparison between ganoderic acid C2 (**8**) and ganolucidic acid B (**10**: $IC_{50} > 199.2 \mu M$), the difference of between both compounds was only functional group (**8**: OH, **10**: H₂) at C-7. Furthermore, the difference of between ganoderic acid C2 (**8**) and ganoderic acid B (**11**: $IC_{50} > 193.5 \mu M$) was only functional group (**8**: OH, **11**: C=O) at C-15. These indicate that all of hydroxyl groups at C-3, C-7 and C-15 in **8** are also important for aldose reductase inhibition.

In a comparison of the chemical structures of ganoderenic acid A (**3**: $IC_{50} = 119.2 \mu M$) and ganoderic acid A (**4**: $IC_{50} > 193.5 \mu M$), the difference of between both compounds was found to be the presence of a double bond at C-20 and C-22. Hence, the presence of double bond moiety between C-20 and C-22 also improved the aldose reductase inhibitory activity.

In summary, for ganoderma acids isolated from *G. lucidum*, the carboxylic group in the side chain is essential for recognizing aldose reductase inhibitory activity and the OH substituent at C-11 dramatically increases aldose reductase inhibitory activity. In the case of ganoderic acid C2 (**8**), all of OH substituent at C-3, C-7 and C-15 are important for potent aldose reductase inhibition. Double bond moiety at C-20 and C-22 is also an important factor for aldose reductase inhibition (Figure 1).

Further studies are ongoing, but these results provide an approach to understanding the structural requirements of lanostane-type triterpenoids from *G. lucidum*. This understanding is needed to develop a new-type of aldose reductase inhibitor.

Acknowledgements

We are thankful to Dr. Miyamoto for optical rotation measurement, to Mr. Matsumoto for HRESIMS measurement and Hitachi Scholarship Foundation - Japan, for postgraduate scholarship to S.F. The costs of publication were supported in part by the Research Grant for Young Investigators of Faculty of Agriculture, Kyushu University.

Supplementary data


Supplementary data associated with this article can be found in supplementary data sheet.

References

- 1 Hudson B.I.; Hofmann M.A.; Bucciarelli L.; Wendt T.; Moser B.; Lu Y.; Qu W.; Stern D.M.; D'Agati V.; Yan S.D.; Yan S.F.; Grant P.J.; Schmidt A.M. *Curr Sci* **2002**, 83, 1515.
- 2 Kinoshita J.H.; Varma S.D.; Fukui H.N. *Jpn J Ophthalmol* **1976**, 20, 399.

- 3 Constantino L.; Rastelli G.; Vianello P.; Cignarella G.; Barlocco D. *Med Res Rev* **1999**, 19, 3.
- 4 Constantino L.; Rastelli G.; Vianello P.; Cignarella G.; Barlocco D. *Exp Opin Ther Pat* **1997**, 7, 843.
- 5 Fatmawati S.; Shimizu K.; Kondo R. *Planta Med* **2010**, 76, 1691.
- 6 (a) Hikino H.; Konno C.; Mirin Y.; Hayashi T. *Planta Med* **1985**, 51, 339; (b) Min B.S.; Gao J.J.; Hattori M.; Lee H.K.; Kim Y.H. *Planta Med* 2001, 67, 811; (c) Ha T.B.T.; Clarissa G.; Wei D.Z.; Line H.C.; Nadine; Isabelle F. *Planta Med* **2000**, 66, 681; (d) Koyama K.; Imaizumi K.; Akiba M.; Kinoshita K.; Takahashi K.; Suzuki A.; Yano S.; Horie S.; Watanabe K.; Naoi Y. *Planta Med* **1997**, 63, 224.
- 7 Patterson R.R.M. *Phytochemistry* **2006**, 67, 1985.
- 8 Toth J.O.; Luu B.; Ourisson G. *Tetrahedron Lett* **1982**, 24, 1081.
- 9 El-Mekkawy S.; Meselhy M.R.; Nakamura N.; Tezuka Y.; Hattori M.; Kakiuchi N.; Shimotohno K.; Kawahata T.; Otake T. *Phytochemistry* **1998**, 49, 1651.
- 10 Liu J.; Kurashiki K.; Shimizu K.; Kondo R. *Biol Pharm Bull* **2006**, 29, 392.
- 11 Giner-Larza E.M.; Máñez S.; Giner-Pons R.M.; Recio M.C.; Ríos J.L. *J Ethnopharmacol* **2000**, 73, 61.
- 12 Cao Q.Z.; Lin Z.B. *Acta Pharmacol Sin* **2004**, 25, 833.
- 13 Yoon S.Y.; Eo S.K.; Kim Y.S.; Lee C.K.; Han S.S. *Arch pharmacol res* **1994**, 17, 438.
- 14 Müller C.I.; Kumagai T.; Kelly J.O.; Seeram N.P.; Heber D.C.; Koeffler H.P. *Leukemia Res* **2006**, 30, 841.
- 15 Wang H.; Ng T.B. *Peptides* **2006**, 27, 27-30.
- 16 Liu J.; Yang F.; Ye L.B.; Yang X.J.; Timani K.A.; Zheng Y.; Wang Y.H. *J Ethnopharmacol* **2004**, 1995, 265.
- 17 Fatmawati S.; Kurashiki K.; Takeno S.; Kim Y.; Shimizu K.; Sato M.; Imaizumi K.; Takahashi K.; Kamiya S.; Kaneko S.; Kondo R. *Phytother Res* **2009**, 23, 28.
- 18 Fatmawati S.; Shimizu K.; Kondo R. *Fitoterapia* **2010**, 81, 1033.
- 19 Gao J.J.; Nakamura N.; Min B.S.; Hirakawa A.; Zuo F.; Hattori M. *Chem Pharm Bull* **2004**, 52, 688.
- 20 Kikuchi T.; Kanomi S.; Murai Y.; Kadota S.; Tsubono K.; Ogita Z. *Chem Pharm Bull* **1986**, 34, 4018.
- 21 Komoda Y.; Nakamura H.; Ishihara S.; Uchida M.; Kohda H.; Yamasaki K. *Chem Pharm Bull* **1985**, 33, 4829.
- 22 Kubota T.; Asaka Y.; Miura I.; Mori H. *Helv Chim Acta* **1982**, 65, 611.
- 23 Nishitoba T.; Sato H.; Sakamura S. *Agric Biol Chem* **1985**, 49, 3637.
- 24 Kikuchi T.; Kanomi S.; Kadota S.; Murai Y.; Tsubono K.; Ogita Z. *Chem Pharm Bull* **1986**, 34, 3695.
- 25 Kikuchi T.; Kanomi S.; Kadota S.; Murai Y.; Tsubono K.; Ogita Z. *Chem Pharm Bull* **1986**, 34, 4030.

- 26 Morigiwa A.; Kitabatake K.; Fujimoto Y.; Ikekawa N. *Chem Pharm Bull* **1986**, 34, 3025.
- 27 Chen Y.; Yan Y.; Xie M.Y.; Nie S.P.; Liu W.; Gong X.F.; Wang Y.X. *J Pharm Biomed Anal* **2008**, 47, 469.
- 28 Yang M.; Wang X.; Guan S.; Xia J.; Sun J.; Guo H.; Guo D.A. *J Am Soc for Mass Spectrom* **2007**, 18, 927.
- 29 Xue B.B.; Guo X.Y.; Che Q.M. *J Chinese Pharm Sci* **2008**, 17, 236.
- 30 The assay was conducted with human recombinant aldose reductase as previously reported¹⁸. The reaction mixture contained 0.15 mM β -NADPH, 10 mM *dl*-glyceraldehyde, 5 μ L of aldose reductase, and 100 μ L of a test sample solution in a total volume of 1.0 mL of 100 mM sodium phosphate buffer (pH 6.2). After the reaction mixtures were incubated at 25°C for 5 min in advance, the reaction was started by the addition of the enzyme, and then the decrease of absorbance was measured at 340 nm for 10 min using a spectrophotometer.
- 31 El-Kabbani O.; Wilson D.K.; Petrash J.M.; Quiococho F.A. *Mol Vis* **1998**, 4, 19.
- 32 Urzhumtsev A.; Favier F.T.; Mitschler A.; Barbantou J.; Barth P.; Urzhumtseva L.; Biellmann J.F.; Podjarny A.D.; Moras D. *Structure* **1997**, 5, 601.

Table 1 Aldose reductase inhibition of compounds **1-17**

Compounds	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	Double bond	IC ₅₀ (μM)
1	=O	β-OH	β-OH	H	=O	H	Δ ^{8,9}	22.8
2	β-OH	=O	=O	β-OH	=O	H	Δ ^{8,9}	>193.5
3	=O	β-OH	=O	H	α-OH	H	Δ ^{8,9} , Δ ^{20,22}	119.2
4	=O	β-OH	=O	H	α-OH	H	Δ ^{8,9}	>193.5
5	=O	=O	=O	H	α-OH	H	Δ ^{8,9}	>194.4
6	=O	β-OH	=O	H	α-OH	CH ₃	Δ ^{8,9}	>189.4
7	=O	β-OH	=O	H	α-OH	CH ₃	Δ ^{8,9} , Δ ^{20,22}	>183.9
8	β-OH	β-OH	=O	H	α-OH	H	Δ ^{8,9}	43.8
9	β-OH	β-OH	=O	β-OH	=O	H	Δ ^{8,9}	>187.9
10	β-OH	H	=O	H	α-OH	H	Δ ^{8,9}	>199.2
11	β-OH	β-OH	=O	H	=O	H	Δ ^{8,9}	>193.5
12	β-OH	β-OH	=O	β-OAc	=O	H	Δ ^{8,9}	>174.2
13	β-OH	=O	=O	β-OAc	=O	H	Δ ^{8,9}	>174.7
14	=O	β-OH	=O	H	=O	H	Δ ^{8,9} , Δ ^{20,22}	>195.3
15	=O	β-OH	=O	H	=O	H	Δ ^{8,9}	>194.4
16	=O	β-OH	β-OH	H	=O	CH ₃	Δ ^{8,9}	>189.4
17	β-OH	β-OH	=O	H	α-OH	CH ₃	Δ ^{8,9}	>183.9




Figure 1 Summarized structure-activity relationships of ganoderma acids from *Ganoderma lucidum* on aldose reductase inhibition

Isolation and extraction

G. lucidum (BMC9049) was provided by Bisoken Inc. (Oita, Japan). The voucher specimen (BMC9049) was deposited at the herbarium of the Department of Forest and Forest Products Sciences, Kyushu University, Japan. The dried and milled fruiting bodies of *G. lucidum* (3 kg) were extracted with CHCl_3 (3×8 L) at room temperature for 24 h. The extract was filtered through ADVANTEC No. 2 filter paper, concentrated under vacuum to obtain CHCl_3 extract (111 g) and then freeze-dried. The concentrated extract (85.5 g) was suspended in H_2O and 5% NaHCO_3 , and CHCl_3 was then used to extract the neutral fraction (59.7 g). The aqueous layer was acidified with 2M HCl to pH 3 and then re-extracted with CHCl_3 to yield the acidic fraction (24.5 g).

A portion of acidic fraction (23.2 g) was chromatographed over silica-gel (550 g of Wakogel C-200, 6 x 36 cm) and eluted with $\text{CHCl}_3/\text{MeOH}$ [1:0 (1000 mL), 50:1 (1020 mL), 40:1 (2665 mL), 30:1 (930 mL), 25:1 (1040 mL), 20:1 (1050 mL), 15:1 (800 mL), 10:1 (1100 mL), 9:1, 8:2, 7:3, 6:4, 1:1 and MeOH, each 1000 mL) to afford 25 fractions (Fr. A1-Fr. A25).

Purification of Fr. A10 (850 mg) was repeatedly chromatographed over silica-gel column (36 g of Wakogel C-200, 3 x 11 cm) and eluted with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (10:0 100 mL, 70:5 75mL, 60:5 65 mL, 45:5 50 mL, 4:1 50 mL, 3:2 50 mL and MeOH 150 mL) to give seven fractions (Fr. A10-1 to Fr. A10-7). Fr. A10-2 to Fr. A10-6 was applied to *p*-HPLC, the mobile phase was composed of 1% $\text{AcOH}/\text{H}_2\text{O}-\text{CH}_3\text{CN}$ (0 min, 60:40; 45 min, 58:42), Inertsil Prep-ODS:20 mm i.d. x 250 mm with flow rate: 8 mL/min and the detecting wavelength was set at 252 nm. This fractionation afforded some compounds with the purity more than 95% included Fr A10-3-7 (**1**, R_T : 21.5 min, 17 mg), Fr. A10-4-3 (**2**, R_T : 14.4 min, 7 mg), Fr A10-3-5 (**3**, R_T :17.8 min, 25 mg), Fr A10-3-6 (**4**, R_T : 19.5 min, 176 mg), Fr A10-3-8 (**5**, R_T : 33.7 min, 13 mg), Fr A10-3-9 (**6**, R_T : 36.5 min, 3 mg), Fr A10-3-10 (**7**, R_T : 39.6 min, 4 mg).

Fr. A19 (618 mg) and Fr. A20 (351 mg) were subjected to *p*-HPLC, the mobile phase was composed of 1% $\text{AcOH}/\text{H}_2\text{O}-\text{CH}_3\text{CN}$ (40 min, 66:34), Inertsil Prep-ODS:20 mm i.d. x 250 mm with flow rate: 8 mL/min and the detecting wavelength was set at 252 nm to give Fr. A19-2 and Fr. A20-6 (**8**, Retention Time (R_T): 20.1 min, 162 mg).

Fr. A15 (106 mg) was subjected to *p*-HPLC, the mobile phase was composed of 2% $\text{AcOH}/\text{H}_2\text{O}-\text{CH}_3\text{CN}$ (0 min, 75:25; 55 min, 70:30; 65 min, 60:40), Agilent Prep-ODS:9.4 mm i.d. x 250 mm with flow rate: 4 mL/min and the detecting wavelength was set at 252 nm to give Fr. A15-5 (**9**, (R_T): 17.8 min, 5 mg) and Fr. A15-16 (**10**, (R_T): 35.1 min, 13 mg).

Fr. A5 (500 mg) was subjected to *p*-HPLC, the mobile phase was composed of 1% $\text{AcOH}/\text{H}_2\text{O}-\text{CH}_3\text{CN}$ (70 min, 35:65) GL sciences, Inc inertsil Prep-ODS:20 mm i.d. x 250 mm with flow rate: 8 mL/min and the detecting wavelength was set at 252 nm to give Fr. A5-2 (**11**, (R_T): 25.9 min, 39 mg), Fr. A5-4 (**12**, (R_T): 28.9 min, 9 mg), Fr. A5-6 (**13**, (R_T): 32.7 min, 12 mg), Fr. A5-8 (**14**, (R_T): 43.9 min, 5 mg) and Fr. A5-9 (**15**, (R_T): 47.8 min, 6 mg).

The compounds were isolated with *p*-HPLC by using WatersTM 600 Controller, WatersTM 486 Tunable absorbance detector, and Waters 600 Multisolvent Delivery System with Inertsil C-18 ODS column (20 mm x 250 mm). HRESIMS were measured with a AccuTOFCS JMS-T100CS mass spectrometer (JEOL). The compound structures were analyzed at 400 MHz on JNM-AL400 FT NMR spectrometer (JEOL). Optical rotation was measured on a JASCO DIP-370 digital Polarimeter. Column chromatography was carried out on silica-gel (Wakogel C-200 particle size 75-150 μ m, Wako). Thin layer chromatography (TLC) was carried out on pre-coated Silica-gel 60 F₂₅₄ plates (0.25 mm, Merck) and spot were detected with I₂ detection and under UV light.

Preparation of methyl esters

Methyl ester of **1** or **8** was synthesized by using trimethylsilyl diazomethane (TMSDA) produced by Nacalai tesque (Kyoto, Japan). 0.01 mol of TMSDA was dropped to 0.01 mol of **1** or **8** which was dissolved in 20% of MeOH and 80% of benzene (100 μ L) and put at room temperature for 30 min. The synthesized compound was dried by nitrogen then extracted with ethyl acetate. Then purification was done by using HPLC (Inertsil ODS: 4.6 mm i.d. x 150 mm) with gradient method, the mobile phase was composed of 1% AcOH/H₂O-CH₃CN (0 min, 70:30; 20 min, 60:40, 25 min, 55:45), flow rate: 1 mL/min and the detecting wavelength was set at 252 nm. The chemical structures of **16** and **17** were confirmed by TLC, HPLC and NMR experiment.